Clinical trial NCT03648996: Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid
Official title: Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Diabetes Mellitus, Type 2
Hyperuricemia
Keywords: arterial stiffness
endothelial dysfunction
type 2 diabetes
hyperuricemia
Lead sponsor: University of Missouri-Columbia
Sponsor class: OTHER
First posted: 2018-08-28
Enrollment: 34
Sex: ALL
Minimum age (years): 40
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Three separate interventions will be undertaken with the primary outcome of improving pulse wave velocity. Initially, age and BMI-matched men and post-menopausal women, all with type 2 diabetes, will be treated with allopurinol (20 men, 20 women) for 6 months, in order to reduce serum uric acid (SUA) concentrations relative to placebo (10 men, 10 women). In a second intervention, dietary fructose will be restricted for a period of 6 months in type 2 diabetes (T2D) subjects who will maintain a stable weight (20 men, 20 women). In a third intervention, dietary fructose will be restricted for a period of 6 months in type 2 diabetes (T2D) subjects who will achieve a caloric deficit and weight reduction (20 men, 20 women). At the beginning and end of each of the studies, measures of arterial stiffness will be combined with assessments of endothelial function (flow-mediated dilation and insulin stimulated leg blood flow), measurements of systemic inflammation and oxidative stress.

Detailed description: Sedentary, overweight and obese subjects diagnosed with T2D, ages 40-75 years old, will be recruited from the local community, via the University of Missouri's Endocrinology Clinic and the primary care clinics. During screening, and after consent, anthropometrics (waist circumference and body composition) will be obtained and fasting blood will be drawn for serum chemistries, A1c, complete blood count, liver and kidney function. Screening will also include completion of an oral glucose tolerance test with measurements of arterial stiffness and assessment of endothelial function. Following screening, eligible subjects will be assigned to one of the four groups (allopurinol, placebo, fructose restriction/isocaloric, or fructose restriction/hypocaloric). Allopurinol will be titrated to achieve a target dose of 300 mg/day. Along with placebo, this arm of the study is double-blinded. A separate group of men and women will be assigned to the isocaloric fructose-restriction study in which dietary fructose is replaced by starch and body weight is held constant. Lastly, a separate group of men and women will be assigned to the hypocaloric fructose-restriction in which baseline caloric intake will be reduced by 500 Calories/day while baseline intakes of protein and fat will remain constant. The subjects in these groups will not be blinded to the dietary treatment but the staff making measurements will be. Subjects in the four groups will be matched for age and BMI.

Eligibility criteria: Inclusion Criteria:

* Men and women ages 40-75 years at randomization
* BMI between 25.1 and 50 kg/m2.
* Type 2 diabetes diagnosed \> 3 months ago. Patients with T2D will be classified based on physician diagnosis.

Exclusion Criteria:

* serum uric acid \< 5.5 mg/dL (for medication/allopurinol and isocaloric low-fructose diet arm)
* habitual diet containing low amount of sugars \< 5% of total energy intake
* recent CVD event (stroke, heart failure hospitalization, revascularization or acute coronary event in the last 12 months).
* abnormal thyroid tests or chronic liver disease
* stage IV renal disease (GFR \<30)
* hyperparathyroidism
* use of azathioprine
* active cancer
* autoimmune diseases
* excessive alcohol consumption (\>14 drinks/week for men, \>7 drinks/week for women)
* current tobacco use
* bodyweight change ≥10% within the last 6 months
* history of gout or uncontrolled hypertension
* A1C \>10 % (only for medication/placebo arm)
* Pregnancy or lactation in women (or women not using contraceptives)

Primary outcomes:
measure: Carotid Femoral Pulse Wave Velocity (cfPWV)
timeFrame: This will be assessed at baseline and 6 months (final). The goal is to assess changes from baseline when compared to final time point.
Secondary outcomes:
measure: Brachial Artery Flow Mediated Dilation (FMD)
timeFrame: Baseline and 6 months (final). The goal is to assess changes from baseline when compared to final time point.
measure: Insulin-stimulated Leg Blood Flow
timeFrame: The goal is to assess insulin stimulated responses in blood flow after 6 mo of intervention.
Other outcomes:
Locations:
city: Columbia
country: United States
facility: University of Missouri
state: Missouri
Study officials:
affiliation: University of Missouri-Columbia
name: Camila Manrique Acevedo, MD
role: PRINCIPAL_INVESTIGATOR
References: